These effects underscore the pleiotropic benefits of SGLT2 inhibitors, which extend beyond their well-established cardiorenal protective roles to encompass the modulation of hematopoiesis, providing a novel therapeutic approach in the management of anemia in cancer patients [67]. The gene discussed is SLC5A2; the disease is anemia (phenotype).